Business Wire

FOURKITES

Share
3T-FourKites Partnership Offers Enhanced Cost and Sustainability Benefits to Customers

Leading real-time supply chain visibility platform FourKites ® today announces that its carrier data will be used to enhance 3T’s global digital transport platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005400/en/

The deal will give 3T’s shipper customers access to FourKites’ supply chain visibility data, bringing them powerful flexibility in the way they use carriers, thereby reducing costs and improving sustainability initiatives.

“FourKites’ broad coverage of carriers in Europe allows us to give our customers a more comprehensive shipment visibility offering as part of our digital transport management software,” says Rob Hutton, Group Sales and Marketing Director at 3T. “That gives them more flexibility in the carriers they can work with, keeping both costs and carbon emissions down.”

3T is a UK-based global SaaS digital transport platform provider, whose transport management solutions dovetail neatly with FourKites’ supply chain visibility offering. 3T’s pioneering cloud-based platform provides a seamless shipper/carrier ecosystem with functionality including transport assignment, rate management and tendering, as well as automatic carrier allocation. It also facilitates supply chain collaboration by enabling AI-driven dynamic planning and execution across multiple accounts, harnessing real-time data to reduce empty running of vehicles.

FourKites is the market leader in real-time, end-to-end supply chain visibility, extending visibility beyond transportation into yards, warehouses, stores and more. The companies’ combined offering signals a paradigm shift in 3T’s ability to not only know the status and position of every shipment, but to also dynamically react to changes from plan.

“Giving 3T customers access to FourKites data will allow them to make better decisions, optimising the way they use carriers,” says Marc Boileau, Senior VP of Sales and Carrier Operations at FourKites Europe. “That has cost benefits for them, it improves their service to customers with almost no administrative work required, and it gives them the most accurate estimated times of arrival available in the market today. We are thrilled to be working together with the 3T team to better support their customer base.”

Carbon reductions

3T already gives customers multiple options to capture carrier data. However, with the addition of FourKites’ real-time supply chain data, 3T customers will now have all the data necessary to complete their operational visibility picture and ultimately help them reduce both carbon emissions and costs through improved resource utilisation.

“We see a huge efficiency opportunity for both shippers and carriers by using data to identify and reduce empty running across the industry. This will be essential to meet our collective environmental targets,” says Rob, "and it’s why this partnership is so exciting for us.”

This is just one aspect of the improved planning shippers can achieve with the 3T-FourKites partnership.

“You’re likely to get a good price by placing a shipment on an empty running truck,” says Marc, “so costs go down. But carriers have fewer empty runs, too, so they see driver productivity improve. It’s win-win. The better your visibility, the better you can plan to optimise your transport.”

In March, FourKites announced its Sustainability Hub, which offers granular emissions tracking, industry benchmarks, analytics and scenario modeling to help customers meet sustainability goals. In addition, the company offers Dynamic Yard ® , a new category of software that connects traditional, siloed yard management software with FourKites’ real-time supply chain data and predictive ETAs to provide insight into driver detention patterns, labor efficiency and more to reduce dwell and inform carbon reduction strategies. Last year, customers who used Dynamic Yard emitted 20% fewer carbon emissions than non-Dynamic Yard users through reductions in truck idle times.

Notes for editors

About FourKites®

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,100 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com .

About 3T

3T Logistics and Technology Group is an award-winning UK head-quartered SaaS transport management technology business with clients including JCB, Klockner Pentaplast and Kraft Heinz. Founded in 2000 as a 4th Party Logistics Provider (4PL), 3T has evolved to become a globally recognised transportation management (TMS) technology provider. The company’s vision and mission remain the same since its inception, to improve service, reduce cost to shippers and carriers and remove empty running through collaboration and the smart use of technology.

To learn more about 3T please visit their website: https://www.3t-ltg.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye